Loading…
The Effect of Citrus aurantium on Non-Small-Cell Lung Cancer: A Research Based on Network and Experimental Pharmacology
Purpose. To screen the main active components of Citrus aurantium through a network pharmacology approach, construct a component-disease target network, explore its molecular mechanism for the treatment of non-small-cell lung cancer (NSCLC), and validate it experimentally. Methods. The active ingred...
Saved in:
Published in: | BioMed research international 2023, Vol.2023 (1), p.6407588-6407588 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c476t-4ea760b80ce6ed7d4fe40975eddfdd95efa3628780dbd4569e9d02601ad35a733 |
---|---|
cites | cdi_FETCH-LOGICAL-c476t-4ea760b80ce6ed7d4fe40975eddfdd95efa3628780dbd4569e9d02601ad35a733 |
container_end_page | 6407588 |
container_issue | 1 |
container_start_page | 6407588 |
container_title | BioMed research international |
container_volume | 2023 |
creator | Yao, Liangliang Zhang, Xuan Huang, Chaoming Cai, Yi Wan, Chunpeng (Craig) |
description | Purpose. To screen the main active components of Citrus aurantium through a network pharmacology approach, construct a component-disease target network, explore its molecular mechanism for the treatment of non-small-cell lung cancer (NSCLC), and validate it experimentally. Methods. The active ingredients in Citrus aurantium and the targets of Citrus aurantium and NSCLC were collected through the Traditional Chinese Medicine Systematic Pharmacology Database and Analysis Platform (TCMSP), GeneCards, and OMIM databases. The protein interaction network was constructed using the STRING database, and the component-disease relationship network graph was analyzed using Cytoscape 3.9.1. The Metascape database can be used for GO and KEGG enrichment analyses. The Kaplan-Meier plotter was applied for overall survival analysis of key targets of Citrus aurantium in the treatment of NSCLC. Real-time PCR (RT-PCR) and Western blotting were used to determine the mRNA and protein levels of key targets of Citrus aurantium for the treatment of NSCLC. Results. Five active ingredients of Citrus aurantium were screened, and 54 potential targets for the treatment of NSCLC were found, of which the key ingredient was nobiletin and the key targets are TP53, CXCL8, ESR1, PPAR-α, and MMP9. GO and KEGG enrichment analyses indicated that the mechanism of nobiletin in treating NSCLC may be related to the regulation of cancer signaling pathway, phosphatidylinositol-3 kinase (PI3K)/protein kinase B (Akt) signaling pathway, lipid and atherosclerosis signaling pathway, and neurodegenerative signaling pathway. The experimental results showed that nobiletin could inhibit the proliferation of NSCLC cells and upregulate the levels of P53 and PPAR-α and suppress the expression of MMP9 (P |
doi_str_mv | 10.1155/2023/6407588 |
format | article |
fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9886468</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A735993372</galeid><sourcerecordid>A735993372</sourcerecordid><originalsourceid>FETCH-LOGICAL-c476t-4ea760b80ce6ed7d4fe40975eddfdd95efa3628780dbd4569e9d02601ad35a733</originalsourceid><addsrcrecordid>eNp9kc2P0zAQxSMEYldlb5yRJS5IENaJHTvmsFKJyodUAYLlbE3jSZMlsYudUPa_x9mWCjjgy1ian968mZckjzP6MsuK4jKnObsUnMqiLO8l5znLeCoynt0__Rk7Sy5CuKHxlZmgSjxMzpiQuSiZOk_21y2SVdNgPRLXkKob_RQITB7s2E0DcZZ8cDb9MkDfpxX2PVlPdksqsDX6V2RJPmNA8HVLXkNAc8fjuHf-GwFryOrnDn03oB2hJ59a8APUrnfb20fJgwb6gBfHuki-vlldV-_S9ce376vlOq25FGPKEaSgm5LWKNBIwxvkVMkCjWmMUQU2wEReypKajeGFUKgMzQXNwLACJGOL5Oqgu5s2A5o6OvHQ6100Bf5WO-j03x3btXrrfmhVloLHGy2SZ0cB775PGEY9dKGOhwCLbgo6lzJTnDLBI_r0H_TGTd7G9WZqdinuHB2pLfSoO9u4OLeeRfVSskIpxmQeqRcHqvYuBI_NyXJG9Ry9nqPXx-gj_uTPNU_w76Aj8PwAtJ01sO_-L_cLDO21UQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2772878673</pqid></control><display><type>article</type><title>The Effect of Citrus aurantium on Non-Small-Cell Lung Cancer: A Research Based on Network and Experimental Pharmacology</title><source>Publicly Available Content (ProQuest)</source><source>Wiley Open Access</source><creator>Yao, Liangliang ; Zhang, Xuan ; Huang, Chaoming ; Cai, Yi ; Wan, Chunpeng (Craig)</creator><contributor>Yadav, Ajar Nath ; Ajar Nath Yadav</contributor><creatorcontrib>Yao, Liangliang ; Zhang, Xuan ; Huang, Chaoming ; Cai, Yi ; Wan, Chunpeng (Craig) ; Yadav, Ajar Nath ; Ajar Nath Yadav</creatorcontrib><description>Purpose. To screen the main active components of Citrus aurantium through a network pharmacology approach, construct a component-disease target network, explore its molecular mechanism for the treatment of non-small-cell lung cancer (NSCLC), and validate it experimentally. Methods. The active ingredients in Citrus aurantium and the targets of Citrus aurantium and NSCLC were collected through the Traditional Chinese Medicine Systematic Pharmacology Database and Analysis Platform (TCMSP), GeneCards, and OMIM databases. The protein interaction network was constructed using the STRING database, and the component-disease relationship network graph was analyzed using Cytoscape 3.9.1. The Metascape database can be used for GO and KEGG enrichment analyses. The Kaplan-Meier plotter was applied for overall survival analysis of key targets of Citrus aurantium in the treatment of NSCLC. Real-time PCR (RT-PCR) and Western blotting were used to determine the mRNA and protein levels of key targets of Citrus aurantium for the treatment of NSCLC. Results. Five active ingredients of Citrus aurantium were screened, and 54 potential targets for the treatment of NSCLC were found, of which the key ingredient was nobiletin and the key targets are TP53, CXCL8, ESR1, PPAR-α, and MMP9. GO and KEGG enrichment analyses indicated that the mechanism of nobiletin in treating NSCLC may be related to the regulation of cancer signaling pathway, phosphatidylinositol-3 kinase (PI3K)/protein kinase B (Akt) signaling pathway, lipid and atherosclerosis signaling pathway, and neurodegenerative signaling pathway. The experimental results showed that nobiletin could inhibit the proliferation of NSCLC cells and upregulate the levels of P53 and PPAR-α and suppress the expression of MMP9 (P<0.05). Conclusion. Citrus aurantium can participate in the treatment of NSCLC through multiple targets and pathways.</description><identifier>ISSN: 2314-6133</identifier><identifier>EISSN: 2314-6141</identifier><identifier>DOI: 10.1155/2023/6407588</identifier><identifier>PMID: 36726839</identifier><language>eng</language><publisher>United States: Hindawi</publisher><subject>1-Phosphatidylinositol 3-kinase ; AKT protein ; Antibodies ; Arteriosclerosis ; Atherosclerosis ; Bioavailability ; Bitter orange ; Cancer therapies ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - genetics ; Care and treatment ; Cell cycle ; Cell proliferation ; Chemical properties ; Chinese medicine ; Citrus ; Citrus aurantium ; Computer programs ; Drugs, Chinese Herbal - pharmacology ; ESR1 protein ; Fruits ; Gelatinase B ; Genes ; Health aspects ; Herbal medicine ; Identification and classification ; Ingredients ; Kinases ; Lipids ; Lung cancer ; Lung cancer, Non-small cell ; Lung Neoplasms - drug therapy ; Lung Neoplasms - genetics ; Matrix Metalloproteinase 9 ; Medical prognosis ; Medicine, Chinese Traditional ; Molecular Docking Simulation ; mRNA ; Non-small cell lung carcinoma ; p53 Protein ; Peroxisome Proliferator-Activated Receptors ; Pharmacology ; Physiological aspects ; Phytochemicals ; Proteins ; Signal transduction ; Signaling ; Software ; Statistical analysis ; Traditional Chinese medicine ; Variance analysis ; Western blotting</subject><ispartof>BioMed research international, 2023, Vol.2023 (1), p.6407588-6407588</ispartof><rights>Copyright © 2023 Liangliang Yao et al.</rights><rights>COPYRIGHT 2023 John Wiley & Sons, Inc.</rights><rights>Copyright © 2023 Liangliang Yao et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. https://creativecommons.org/licenses/by/4.0</rights><rights>Copyright © 2023 Liangliang Yao et al. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c476t-4ea760b80ce6ed7d4fe40975eddfdd95efa3628780dbd4569e9d02601ad35a733</citedby><cites>FETCH-LOGICAL-c476t-4ea760b80ce6ed7d4fe40975eddfdd95efa3628780dbd4569e9d02601ad35a733</cites><orcidid>0000-0001-6892-016X ; 0000-0003-2296-222X ; 0000-0002-8435-5954</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2772878673/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2772878673?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,4024,25753,27923,27924,27925,37012,37013,44590,74998</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36726839$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Yadav, Ajar Nath</contributor><contributor>Ajar Nath Yadav</contributor><creatorcontrib>Yao, Liangliang</creatorcontrib><creatorcontrib>Zhang, Xuan</creatorcontrib><creatorcontrib>Huang, Chaoming</creatorcontrib><creatorcontrib>Cai, Yi</creatorcontrib><creatorcontrib>Wan, Chunpeng (Craig)</creatorcontrib><title>The Effect of Citrus aurantium on Non-Small-Cell Lung Cancer: A Research Based on Network and Experimental Pharmacology</title><title>BioMed research international</title><addtitle>Biomed Res Int</addtitle><description>Purpose. To screen the main active components of Citrus aurantium through a network pharmacology approach, construct a component-disease target network, explore its molecular mechanism for the treatment of non-small-cell lung cancer (NSCLC), and validate it experimentally. Methods. The active ingredients in Citrus aurantium and the targets of Citrus aurantium and NSCLC were collected through the Traditional Chinese Medicine Systematic Pharmacology Database and Analysis Platform (TCMSP), GeneCards, and OMIM databases. The protein interaction network was constructed using the STRING database, and the component-disease relationship network graph was analyzed using Cytoscape 3.9.1. The Metascape database can be used for GO and KEGG enrichment analyses. The Kaplan-Meier plotter was applied for overall survival analysis of key targets of Citrus aurantium in the treatment of NSCLC. Real-time PCR (RT-PCR) and Western blotting were used to determine the mRNA and protein levels of key targets of Citrus aurantium for the treatment of NSCLC. Results. Five active ingredients of Citrus aurantium were screened, and 54 potential targets for the treatment of NSCLC were found, of which the key ingredient was nobiletin and the key targets are TP53, CXCL8, ESR1, PPAR-α, and MMP9. GO and KEGG enrichment analyses indicated that the mechanism of nobiletin in treating NSCLC may be related to the regulation of cancer signaling pathway, phosphatidylinositol-3 kinase (PI3K)/protein kinase B (Akt) signaling pathway, lipid and atherosclerosis signaling pathway, and neurodegenerative signaling pathway. The experimental results showed that nobiletin could inhibit the proliferation of NSCLC cells and upregulate the levels of P53 and PPAR-α and suppress the expression of MMP9 (P<0.05). Conclusion. Citrus aurantium can participate in the treatment of NSCLC through multiple targets and pathways.</description><subject>1-Phosphatidylinositol 3-kinase</subject><subject>AKT protein</subject><subject>Antibodies</subject><subject>Arteriosclerosis</subject><subject>Atherosclerosis</subject><subject>Bioavailability</subject><subject>Bitter orange</subject><subject>Cancer therapies</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - genetics</subject><subject>Care and treatment</subject><subject>Cell cycle</subject><subject>Cell proliferation</subject><subject>Chemical properties</subject><subject>Chinese medicine</subject><subject>Citrus</subject><subject>Citrus aurantium</subject><subject>Computer programs</subject><subject>Drugs, Chinese Herbal - pharmacology</subject><subject>ESR1 protein</subject><subject>Fruits</subject><subject>Gelatinase B</subject><subject>Genes</subject><subject>Health aspects</subject><subject>Herbal medicine</subject><subject>Identification and classification</subject><subject>Ingredients</subject><subject>Kinases</subject><subject>Lipids</subject><subject>Lung cancer</subject><subject>Lung cancer, Non-small cell</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - genetics</subject><subject>Matrix Metalloproteinase 9</subject><subject>Medical prognosis</subject><subject>Medicine, Chinese Traditional</subject><subject>Molecular Docking Simulation</subject><subject>mRNA</subject><subject>Non-small cell lung carcinoma</subject><subject>p53 Protein</subject><subject>Peroxisome Proliferator-Activated Receptors</subject><subject>Pharmacology</subject><subject>Physiological aspects</subject><subject>Phytochemicals</subject><subject>Proteins</subject><subject>Signal transduction</subject><subject>Signaling</subject><subject>Software</subject><subject>Statistical analysis</subject><subject>Traditional Chinese medicine</subject><subject>Variance analysis</subject><subject>Western blotting</subject><issn>2314-6133</issn><issn>2314-6141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNp9kc2P0zAQxSMEYldlb5yRJS5IENaJHTvmsFKJyodUAYLlbE3jSZMlsYudUPa_x9mWCjjgy1ian968mZckjzP6MsuK4jKnObsUnMqiLO8l5znLeCoynt0__Rk7Sy5CuKHxlZmgSjxMzpiQuSiZOk_21y2SVdNgPRLXkKob_RQITB7s2E0DcZZ8cDb9MkDfpxX2PVlPdksqsDX6V2RJPmNA8HVLXkNAc8fjuHf-GwFryOrnDn03oB2hJ59a8APUrnfb20fJgwb6gBfHuki-vlldV-_S9ce376vlOq25FGPKEaSgm5LWKNBIwxvkVMkCjWmMUQU2wEReypKajeGFUKgMzQXNwLACJGOL5Oqgu5s2A5o6OvHQ6100Bf5WO-j03x3btXrrfmhVloLHGy2SZ0cB775PGEY9dKGOhwCLbgo6lzJTnDLBI_r0H_TGTd7G9WZqdinuHB2pLfSoO9u4OLeeRfVSskIpxmQeqRcHqvYuBI_NyXJG9Ry9nqPXx-gj_uTPNU_w76Aj8PwAtJ01sO_-L_cLDO21UQ</recordid><startdate>2023</startdate><enddate>2023</enddate><creator>Yao, Liangliang</creator><creator>Zhang, Xuan</creator><creator>Huang, Chaoming</creator><creator>Cai, Yi</creator><creator>Wan, Chunpeng (Craig)</creator><general>Hindawi</general><general>John Wiley & Sons, Inc</general><general>Hindawi Limited</general><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7QO</scope><scope>7T7</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>CWDGH</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-6892-016X</orcidid><orcidid>https://orcid.org/0000-0003-2296-222X</orcidid><orcidid>https://orcid.org/0000-0002-8435-5954</orcidid></search><sort><creationdate>2023</creationdate><title>The Effect of Citrus aurantium on Non-Small-Cell Lung Cancer: A Research Based on Network and Experimental Pharmacology</title><author>Yao, Liangliang ; Zhang, Xuan ; Huang, Chaoming ; Cai, Yi ; Wan, Chunpeng (Craig)</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c476t-4ea760b80ce6ed7d4fe40975eddfdd95efa3628780dbd4569e9d02601ad35a733</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>1-Phosphatidylinositol 3-kinase</topic><topic>AKT protein</topic><topic>Antibodies</topic><topic>Arteriosclerosis</topic><topic>Atherosclerosis</topic><topic>Bioavailability</topic><topic>Bitter orange</topic><topic>Cancer therapies</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - genetics</topic><topic>Care and treatment</topic><topic>Cell cycle</topic><topic>Cell proliferation</topic><topic>Chemical properties</topic><topic>Chinese medicine</topic><topic>Citrus</topic><topic>Citrus aurantium</topic><topic>Computer programs</topic><topic>Drugs, Chinese Herbal - pharmacology</topic><topic>ESR1 protein</topic><topic>Fruits</topic><topic>Gelatinase B</topic><topic>Genes</topic><topic>Health aspects</topic><topic>Herbal medicine</topic><topic>Identification and classification</topic><topic>Ingredients</topic><topic>Kinases</topic><topic>Lipids</topic><topic>Lung cancer</topic><topic>Lung cancer, Non-small cell</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - genetics</topic><topic>Matrix Metalloproteinase 9</topic><topic>Medical prognosis</topic><topic>Medicine, Chinese Traditional</topic><topic>Molecular Docking Simulation</topic><topic>mRNA</topic><topic>Non-small cell lung carcinoma</topic><topic>p53 Protein</topic><topic>Peroxisome Proliferator-Activated Receptors</topic><topic>Pharmacology</topic><topic>Physiological aspects</topic><topic>Phytochemicals</topic><topic>Proteins</topic><topic>Signal transduction</topic><topic>Signaling</topic><topic>Software</topic><topic>Statistical analysis</topic><topic>Traditional Chinese medicine</topic><topic>Variance analysis</topic><topic>Western blotting</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yao, Liangliang</creatorcontrib><creatorcontrib>Zhang, Xuan</creatorcontrib><creatorcontrib>Huang, Chaoming</creatorcontrib><creatorcontrib>Cai, Yi</creatorcontrib><creatorcontrib>Wan, Chunpeng (Craig)</creatorcontrib><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Proquest Health & Medical Complete</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Advanced Technologies & Aerospace Database (1962 - current)</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Middle East & Africa Database</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BioMed research international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yao, Liangliang</au><au>Zhang, Xuan</au><au>Huang, Chaoming</au><au>Cai, Yi</au><au>Wan, Chunpeng (Craig)</au><au>Yadav, Ajar Nath</au><au>Ajar Nath Yadav</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Effect of Citrus aurantium on Non-Small-Cell Lung Cancer: A Research Based on Network and Experimental Pharmacology</atitle><jtitle>BioMed research international</jtitle><addtitle>Biomed Res Int</addtitle><date>2023</date><risdate>2023</risdate><volume>2023</volume><issue>1</issue><spage>6407588</spage><epage>6407588</epage><pages>6407588-6407588</pages><issn>2314-6133</issn><eissn>2314-6141</eissn><abstract>Purpose. To screen the main active components of Citrus aurantium through a network pharmacology approach, construct a component-disease target network, explore its molecular mechanism for the treatment of non-small-cell lung cancer (NSCLC), and validate it experimentally. Methods. The active ingredients in Citrus aurantium and the targets of Citrus aurantium and NSCLC were collected through the Traditional Chinese Medicine Systematic Pharmacology Database and Analysis Platform (TCMSP), GeneCards, and OMIM databases. The protein interaction network was constructed using the STRING database, and the component-disease relationship network graph was analyzed using Cytoscape 3.9.1. The Metascape database can be used for GO and KEGG enrichment analyses. The Kaplan-Meier plotter was applied for overall survival analysis of key targets of Citrus aurantium in the treatment of NSCLC. Real-time PCR (RT-PCR) and Western blotting were used to determine the mRNA and protein levels of key targets of Citrus aurantium for the treatment of NSCLC. Results. Five active ingredients of Citrus aurantium were screened, and 54 potential targets for the treatment of NSCLC were found, of which the key ingredient was nobiletin and the key targets are TP53, CXCL8, ESR1, PPAR-α, and MMP9. GO and KEGG enrichment analyses indicated that the mechanism of nobiletin in treating NSCLC may be related to the regulation of cancer signaling pathway, phosphatidylinositol-3 kinase (PI3K)/protein kinase B (Akt) signaling pathway, lipid and atherosclerosis signaling pathway, and neurodegenerative signaling pathway. The experimental results showed that nobiletin could inhibit the proliferation of NSCLC cells and upregulate the levels of P53 and PPAR-α and suppress the expression of MMP9 (P<0.05). Conclusion. Citrus aurantium can participate in the treatment of NSCLC through multiple targets and pathways.</abstract><cop>United States</cop><pub>Hindawi</pub><pmid>36726839</pmid><doi>10.1155/2023/6407588</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0001-6892-016X</orcidid><orcidid>https://orcid.org/0000-0003-2296-222X</orcidid><orcidid>https://orcid.org/0000-0002-8435-5954</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2314-6133 |
ispartof | BioMed research international, 2023, Vol.2023 (1), p.6407588-6407588 |
issn | 2314-6133 2314-6141 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9886468 |
source | Publicly Available Content (ProQuest); Wiley Open Access |
subjects | 1-Phosphatidylinositol 3-kinase AKT protein Antibodies Arteriosclerosis Atherosclerosis Bioavailability Bitter orange Cancer therapies Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Care and treatment Cell cycle Cell proliferation Chemical properties Chinese medicine Citrus Citrus aurantium Computer programs Drugs, Chinese Herbal - pharmacology ESR1 protein Fruits Gelatinase B Genes Health aspects Herbal medicine Identification and classification Ingredients Kinases Lipids Lung cancer Lung cancer, Non-small cell Lung Neoplasms - drug therapy Lung Neoplasms - genetics Matrix Metalloproteinase 9 Medical prognosis Medicine, Chinese Traditional Molecular Docking Simulation mRNA Non-small cell lung carcinoma p53 Protein Peroxisome Proliferator-Activated Receptors Pharmacology Physiological aspects Phytochemicals Proteins Signal transduction Signaling Software Statistical analysis Traditional Chinese medicine Variance analysis Western blotting |
title | The Effect of Citrus aurantium on Non-Small-Cell Lung Cancer: A Research Based on Network and Experimental Pharmacology |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T21%3A59%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Effect%20of%20Citrus%20aurantium%20on%20Non-Small-Cell%20Lung%20Cancer:%20A%20Research%20Based%20on%20Network%20and%20Experimental%20Pharmacology&rft.jtitle=BioMed%20research%20international&rft.au=Yao,%20Liangliang&rft.date=2023&rft.volume=2023&rft.issue=1&rft.spage=6407588&rft.epage=6407588&rft.pages=6407588-6407588&rft.issn=2314-6133&rft.eissn=2314-6141&rft_id=info:doi/10.1155/2023/6407588&rft_dat=%3Cgale_pubme%3EA735993372%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c476t-4ea760b80ce6ed7d4fe40975eddfdd95efa3628780dbd4569e9d02601ad35a733%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2772878673&rft_id=info:pmid/36726839&rft_galeid=A735993372&rfr_iscdi=true |